Detalhe da pesquisa
1.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697166
2.
How I treat high-risk multiple myeloma.
Blood
; 139(19): 2889-2903, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34727187
3.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
4.
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
Haematologica
; 109(3): 888-894, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646655
5.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439329
6.
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Eur J Haematol
; 112(5): 701-713, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146208
7.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
8.
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells.
Int J Mol Sci
; 24(13)2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37445991
9.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638723
10.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608183
11.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716957
12.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Am J Hematol
; 97(12): 1607-1615, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36198076
13.
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Am J Hematol
; 97(7): 877-884, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35389534
14.
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Int J Mol Sci
; 23(20)2022 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36293315
15.
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.
Lancet Oncol
; 22(3): e119-e130, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545067
16.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774221
17.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
18.
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Br J Haematol
; 194(3): 496-507, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724461
19.
Imaging in multiple myeloma: How? When?
Blood
; 133(7): 644-651, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587527
20.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261295